Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of personalized neoantigen-pulsed autologous dendritic cell vaccine in advanced solid tumors
ChiCTR2100054020Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Dec 2019
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of neoantigen-pulsed autologous dendritic cell vaccine in Nonhematologic neoplasms, sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Safety. Started Dec 2019; status: recruiting.
02
Drugs
neoantigen-pulsed autologous dendritic cell vaccine
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2100054020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054020.